Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres

[1] Tomer Y(2003)Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function Endocr. Rev. 24 694-717

[2] Davies TF(2007)Really significant genes for autoimmune thyroid disease do not exist – so how can we predict disease? Thyroid 17 1027-1029

[3] Davies TF(2013)Smoking and thyroid Clin. Endocrinol. 79 145-151

[4] Wiersinga WM(2016)Adjuvant treatment of Graves´ disease with diclofenac-safety, effects on ophthalmopathy and antibody concentrations Eur. Thyroid J. 5 50-57

[5] Lantz M(1999)The combination of absent thyroid peroxidise antibodies and high thyroid-stimulating immunoglobulin levels in GD identifies a group at markedly increased risk of ophthalmopathy Thyroid 9 1175-1180

[6] Calissendorff J(2014)Increased TRAb and/or low anti-TPO titers at diagnosis of Graves´ disease (GD) are associated with an increased risk of developing ophthalmopathy after onset of GD Exp. Clin. Endocrinol. Diabetes 122 113-118

[7] Träisk F(2009)Thyroid associated ophthalmopathy ocurrence after treatment for Graves´ hyperthyroidism with iodine-131 or anti-thyroid drugs J. Clin. Endocrinol. Metab. 94 3700-3707

[8] Tallstedt L(2008)TSH-receptor autoimmunity in Graves´s disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5 year prospective randomized study Eur. J. Endocrinol. 158 69-75

[9] Planck T(1982)Effect of radioiodine on stimulatory activity of Graves’ immunoglobulins Clin. Endocrinol. 16 537-543

[10] Törring O(1980)A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves’ disease treated by subtotal thyroidectomy or radioactive iodine J. Clin. Endocrinol. Metab. 50 1005-1010

[1] Tomer Y(2003)Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function Endocr. Rev. 24 694-717

[2] Davies TF(2007)Really significant genes for autoimmune thyroid disease do not exist – so how can we predict disease? Thyroid 17 1027-1029

[3] Davies TF(2013)Smoking and thyroid Clin. Endocrinol. 79 145-151

[4] Wiersinga WM(2016)Adjuvant treatment of Graves´ disease with diclofenac-safety, effects on ophthalmopathy and antibody concentrations Eur. Thyroid J. 5 50-57

[5] Lantz M(1999)The combination of absent thyroid peroxidise antibodies and high thyroid-stimulating immunoglobulin levels in GD identifies a group at markedly increased risk of ophthalmopathy Thyroid 9 1175-1180

[6] Calissendorff J(2014)Increased TRAb and/or low anti-TPO titers at diagnosis of Graves´ disease (GD) are associated with an increased risk of developing ophthalmopathy after onset of GD Exp. Clin. Endocrinol. Diabetes 122 113-118

[7] Träisk F(2009)Thyroid associated ophthalmopathy ocurrence after treatment for Graves´ hyperthyroidism with iodine-131 or anti-thyroid drugs J. Clin. Endocrinol. Metab. 94 3700-3707

[8] Tallstedt L(2008)TSH-receptor autoimmunity in Graves´s disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5 year prospective randomized study Eur. J. Endocrinol. 158 69-75

[9] Planck T(1982)Effect of radioiodine on stimulatory activity of Graves’ immunoglobulins Clin. Endocrinol. 16 537-543

[10] Törring O(1980)A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves’ disease treated by subtotal thyroidectomy or radioactive iodine J. Clin. Endocrinol. Metab. 50 1005-1010